Skip to main content
CRISPR Therapeutics to resume gene therapy study
10/11/2018

The FDA lifted a clinical hold on CRISPR Therapeutics' studies of CTX001, a gene therapy being developed to treat sickle cell disease and beta-thalassemia.

Full Story: